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Summary. Background: Thiol isomerases are a family of
endoplasmic reticulum enzymes which orchestrate redox-based
modiﬁcationsofproteindisulphidebonds.Previousstudieshave
identiﬁedimportantroles for thethiol isomerasesPDIandERp5
in the regulationofnormalplatelet function. Aim:Recently, we
demonstrated the presence of a further ﬁve thiol isomerases at
the platelet surface. In this report we aim to report the role of
one of these enzymes – ERp57 in the regulation of platelet
function. Methods/Results: Using enzyme activity function
blocking antibodies, we demonstrate a role for ERp57 in
platelet aggregation, dense granule secretion, ﬁbrinogen bind-
ing, calcium mobilisation and thrombus formation under
arterial conditions. In addition to the eﬀects of ERp57 on
isolated platelets, we observe the presence of ERp57 in the
developing thrombus in vivo. Furthermore the inhibition of
ERp57 function was found to reduce laser-injury induced
arterial thrombus formation in a murine model of thrombo-
sis. Conclusions: These data suggest that ERp57 is important
for normal platelet function and opens up the possibility that
the regulation of platelet function by a range of cell surface thiol
isomerases may represent a broad paradigm for the regulation
of haemostasis and thrombosis.
Keywords: ERp5, ERp57, PDI, platelet activation, redox reg-
ulation, thiol isomerase.
Introduction
Platelets contain a number of thiol isomerase enzymes; PDI
[1], ERp5 [2], ERp57, ERp72, ERp44, ERp29 and TMX3
[3]. These are present on the surface membrane of the resting
platelet and the levels of which are found to increase during
platelet activation [2,4]. Enzyme activity blocking antibodies
raised against PDI and ERp5 have been used to demonstrate
that the activity of these enzymes contributes to a range of
platelet responses including aggregation, adhesion, granule
secretion and integrin activation [2,5–7]. Additionally, more
recent studies using in vivo measurements of thrombus
formation show the presence of PDI secreted from platelets
and endothelial cells following vascular injury and demon-
strate its importance in the thrombus formation process and
the activation of coagulation pathways leading to ﬁbrin
deposition [8,9]. The discovery of a number of thiol
isomerases that are likely to be catalytically competent at
the platelet surface is indicative of the existence of an
important regulatory paradigm shared by selected thiol
isomerases [3]. In this study we investigate the role of the
recently identiﬁed platelet-surface thiol isomerase, ERp57 in
human platelet responses and thrombus formation. ERp57 is
a 505 amino acid soluble ER protein [10,11] which is the
closest known homologue of PDI, sharing 33% total
sequence identity [12,13]. Previous work has attributed
important roles for ERp57 in a number of different cell
scenarios including; folding of inﬂuenza haemagglutinin [14],
as a component of MHC peptide loading complexes [15], the
modulation of SERCA 2b function in oocytes [16], tran-
scription factor activation [17,18] and the regulation of
calcium-mediated capacitation in spermatozoa [19]. In this
study, using enzyme activity blocking antibodies, we dem-
onstrate for the ﬁrst time that cell-surface ERp57 is a key
player in the regulation of normal platelet aggregation,
integrin activation and signalling. Physiologically, ERp57 is
secreted upon vascular injury and accumulates in the
thrombus where it regulates the activation and recruitment
of other platelets.
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Methods
Reagents
Cross linked collagen-related peptide (CRP-XL) was pur-
chased from Prof Richard Farndale (University of Cambridge,
Cambridge, UK), Protein-G sepharose, cyanogen bromide-
activated sepharose and bovine protein disulphide isomerase
were from Sigma (Poole, UK). The IV.3 hybridoma cell line
(HB-217) was from ATCC (Manassas, VA, USA) and F(ab)¢
fragments of puriﬁed IV.3 antibody were generated using the
Immunopure F(ab)¢ puriﬁcation kit (Pierce, Northumberland,
UK).pGEX6P1expressionvectorandPreScissionproteasewere
from GE Healthcare (Buckinghamshire, UK). Anti-platelet
factor 4 antibody was from Accurate Chemical and Scientiﬁc
Corporation (New York, USA). Anti-human P-selectin phyco-
erythrin-conjugate was from BD Biosciences (Oxford, UK) and
Anti-human ﬁbrinogen FITC-conjugated antibody was from
Dako (Cambridgeshire, UK). Anti-GPIb Alexa-488 conjugate
was fromEmfretAnalytics (Germany)Alexa-488Sheep IgGwas
from Jackson ImmunoResearch Laboratories (West Grove,
Philladelphia, PA, USA). Monoclonal anti-ERp57 (ab13506)
and puriﬁed mouse IgG was from Abcam (Cambridge, UK).
Recombinant humanERp5was puriﬁed as described previously
[2] and a construct for the expression of mouse ERp72 was
obtained from Dr Mike Green, (St Louis University, USA),
DNAwas subcloned into pGEX6P1 vector and protein puriﬁed
as described below for ERp57.
Antibody preparation
A full length human ERp57 cDNA clone (provided by Prof R
Sitia, Instituto Scientiﬁco San Raffaele, Italy) was cloned into
the pGEX6P1 expression vector to direct the expression of a
soluble ERp57-glutathione s-transferase (ERp57-GST) fusion
protein in Escherichia coli. The fusion protein was puriﬁed by
afﬁnity chromatography on a glutathione agarose column
followed by gel ﬁltration on a Superdex 75 Column (GE
Healthcare). ERp57 was cleaved from the GST-fusion partner
using PreScission protease following the manufacturers pro-
tocols (GE Healthcare) and used as an immunogen to raise
polyclonal antibodies in sheep. Antibodies were initially
puriﬁed from serum using protein-G sepharose chromatogra-
phy and then afﬁnity puriﬁed usingERp57 protein immobilised
on cyanogen bromide-activated sepharose. Antibodies were
eluted from the afﬁnity column as described previously [20] and
dialysed against PBS. The ability of afﬁnity puriﬁed antibody
fractions to inhibit the enzymic activity of recombinant ERp57
was tested by ﬂuorimetric assay based on the reversal of self
quenching of the ﬂuorophore dieosin glutathione disulphide
(DI-E-GSSG) by reducing agents and enzymes, assayed using a
ﬂuorimeter at 525 nm [21]. Antibody cross reactivity assays
using recombinant ERp72, PDI and ERp5were performed in a
similar manner. Anti-ERp57 used for in vivo experiments was
labelled with Alexa-488 using a Microscale labelling kit
(Invitrogen, Paisley, UK).
Platelet preparation and stimulation
Washed human platelets from drug-free donors were prepared
by differential centrifugation and suspended to a density of
4 · 108 cells mL)1 in Tyrodes-HEPES buffer (134 mM NaCl,
2.9 mM KCl, 0.34 mM Na2HPO4, 12 mM NaHCO3, 20 mM
HEPES, 1 mM MgCl2 and 5 mM glucose, pH 7.3). The low
afﬁnity IgG receptor FccRIIa, was blocked by pre-incubation
with a saturating concentration (6.8 lg mL)1) of the F(ab)¢
fragment of mAb IV.3 [22] for 1 min and then monoclonal
anti-ERp57 (Abcam), anti-ERp57, puriﬁed mouse IgG or pre-
immune sheep IgG added for 5 min prior to stimulation and
brieﬂy stirred. Platelets were stimulated using CRP-XL
(1 lg mL)1) for 90 s in an optical aggregometer (Chronolog,
Havertown, PA, USA) with continuous stirring.
SDS-PAGE and immunoblotting
Protein separation by reducing SDS–polyacrylamide gel elec-
trophoresis (SDS-PAGE) was performed using 4% stacking
and 10% resolving gels. Whole platelet lysate (WPL) or
recombinant proteins were transferred to PVDFmembrane by
means of semi-dry western blotting (Bio-Rad) and membranes
blocked using 5% (w/v) BSA in Tris-buffered saline/Tween
(TBS-T, 20 mM Tris, 0.14 M NaCl, 0.01% Tween, pH 7.6).
Diluted primary antibody (anti-ERp57 1:1000 in 2% (w/v)
skimmed milk powder/TBS-T) and species-speciﬁc secondary
antibody (HRP-conjugated anti-sheep IgG at a dilution of
1:4000) were added for 1 h at room temperature. Blots were
washed for 1 h in multiple changes of TBS-T and then
visualised using an enhanced chemiluminescence system.
Platelet granule secretion
ATP secretion from dense granules was measured using lumi-
aggregometry. Human platelet rich plasma (PRP) adjusted to
4 · 108 cells mL)1 was pre-incubated with 6.8 lg mL)1 of the
F(ab)¢ fragment of the mAb IV.3 (6.8 lg mL)1) and anti-
ERp57 or pre-immune IgG. Chronolume reagent (50 lL) was
added 2 min prior to stimulation with CRP-XL (1 lg mL)1).
Secretion was recorded for 180 s.
a-Granule secretion was measured by quantifying levels of
secreted platelet factor 4 (PF4) by ELISA. Washed human
platelets (4 · 108 cells mL)1), pre-incubatedwith anti-ERp57 or
pre-immune IgG were stimulated for 90 s using CRP-XL
(1 lg mL)1) in the presence of EGTA (1 mM), indomethacin
(10 lM)andapyrase (2 U mL)1). Stimulationwas terminatedby
the addition of 6% (v/v) glutaraldehyde and supernatants
obtained by centrifugation. Ten microliters supernatant (1:10
dilution in 0.1 M sodium bicarbonate) was bound to a 96 well
plate in triplicate. Following washes with 1 · TBS-T, wells were
blocked using 5% (w/v) protease-free BSA. One hundred
microliters anti-PF4 antibody (10 ng mL)1 in 5% (w/v) BSA)
then 100 lLanti-rabbit peroxidiseHRP-conjugate (1:1000)were
added foranhour.Followingwashes, the reactionwasdeveloped
by adding 175 lL 3,3¢,5,5¢- tetramethyl-benzidine (TMB) sub-
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strate then 50 lL0.5 Mhydrochloric acid and absorption read at
a wavelength of 450 nm. Alternatively, P-selectin exposure was
measured by ﬂow cytometry as reported previously [23].
Calcium flux measurement in vitro
Cytosolic calcium ﬂux (mobilisation from intracellular stores
and inﬂux) was measured by spectroﬂuorimetry [24]. PRP was
incubated with Fluo-4NW for 30 min. 6.8 lg mL)1 F(ab)¢
fragment of mAb IV.3 was added for 1 min, then either anti-
ERp57 or pre-immune IgG were added 5 min prior to
stimulation. Treated PRP was added to the wells of a
reﬂective-bottomedmicrotitre plate and calciumﬂuxmeasured,
following stimulation with 1 lg mL)1 CRP-XL, using a
FLUOstar OPTIMA ﬂuorescence microplate reader (BMG
Lab tech, Buckinghamshire, UK).
Activation of aIIbb3
The activation state of integrin aIIbb3 on human platelets was
measured by ﬂow cytometry. PRP (4 · 108 cells mL)1) treated
with 10 lM indomethacin and 2 U mL)1apyrase was incu-
bated with 6.8 lg mL)1of the mAb IV.3 F(ab)¢ fragment for
1 min and then anti-ERp57 or pre-immune IgG for a further
5 min. Following stimulation using CRP-XL (1 lg mL)1) for
90 s, platelet-ﬁbrinogen binding was determined by ﬂow
cytometry as described previously [23].
Thrombus formation under arterial flow conditions
Whole human blood was incubated for 20 min with the
ﬂuorescent dye DIOC6 (1 lM). Blood was perfused over
collagen coated capillaries at arterial shear rate (1000 s)1) as
described by Kulkarni et al. [25] in the presence of anti-ERp57
or pre-immune IgG for 3 min. Thrombi were analysed by
confocal microscopy. Images from random ﬁelds throughout
each capillary were captured and Z-stack images obtained at
2 lm intervals which were compiled into a 3D image for the
calculation of thrombus volume.
Platelet static adhesion assay
Human platelet adhesion to collagen and ﬁbrinogen was
measured by static adhesion assay and quantiﬁed by the
measurement of platelet derived acid phosphatase as described
previously [26].
Clot retraction assay
Human PRP (4 · 108 cells mL)1) was incubated with either
anti-ERp57 or pre-immune IgG. Red blood cells (10 lL) were
added to enable visualisation of the developing clot and clot
formation initiated by the addition of thrombin (1 U mL)1).
Clot retraction was allowed to proceed for 2 h around a sealed
glass pipette. Clot weights were measured and data normalised
to pre-immune IgG controls.
Measurement of arterial thrombus formation in vivo
Intravital microscopy and data analysis were performed as
previously described [27]. C57BL/6 mice were anaesthetised by
intraperitoneal injection of ketamine (125 mg kg)1), xylazine
(12.5 mg kg)1) and atropine (0.25 mg kg)1). Platelets labelled
with Alexa-488-conjugated anti-GPIb antibody (0.2 lg g)1
weight) were infused through a jugular vein cannula. Following
exposure of the testicular cremaster muscle, non-immune IgG
or anti-ERp57 (both 2.5 lg g)1 mouse weight) were infused
and injury upon the cremaster arteriole wall induced using a
Micropoint Ablation Laser (Andor Technology, Belfast, UK).
The laser injury was optimised to result in the exposure of
subendothelial collagen detected through binding of anti-
collagen antibodies (data not shown). Thrombi were observed
using an upright Olympus BX microscope (Olympus, Essex,
UK) and images were captured using a Hamamatsu (Ham-
amatsu Photonics, Hertfordshire, UK) charge-coupled device
camera and data analyzed using Slidebook software Version
5.0 (Intelligent Imaging Innovations, Denver, CO, USA). For
the detection of ERp57 at the site of the thrombus, Alexa-488-
labelled anti-ERp57 or Alexa-488-labelled sheep non-immune
IgG was infused at a concentration of 0.5 lg g)1 mouse weight
and arterial thrombus formation measured as described above.
Animal Experiments were approved by the University of
Reading Local Ethical Review Panel and authorized by a UK
Home Ofﬁce Licence.
Data analysis
Data were analysed using Microsoft Excel and GraphPad
Prism software and statistical analysis performed using a paired
Students t-test. For platelet aggregation, dense granule secre-
tion and enzyme activity, pre-immune values in each assaywere
deﬁned as 100% and values normalised to these values to aid
clarity. Non-normalised data was used for all statistical analysis
and where possible raw data is displayed. Data where
P < 0.05 were considered signiﬁcant.
Results
Affinity purified anti-ERp57 inhibits ERp57 enzyme activity
Anti-ERp57 antibodies raised in sheep were puriﬁed using
immobilised ERp57 protein afﬁnity chromatography in order
to select enzyme-activity blocking fractions while preventing
cross-reactivity. Antibody sub-populations were analysed by
SDS-PAGE and a ﬂuorescence-based enzyme assay using the
self-quenching ﬂuorescent substrate Di-E-GSSG was used to
determine speciﬁcity and establish which antibodies selec-
tively blocked ERp57 activity. As observed previously for
ERp5 [2], afﬁnity puriﬁcation of anti-ERp57 IgG enabled
the selection of potent and enzyme-selective inhibitory
antibodies which were used to assess the role of ERp57 in
platelet regulation. Immunoblots (Fig. 1A) demonstrate that
anti-ERp57 recognises a single band in samples of whole
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platelet lysate (WPL) and recombinant ERp57 and is able to
detect ERp57 recombinant protein down to 16 ng mL)1,
suggesting that anti-ERp57 is both speciﬁc and sensitive.
Recombinant ERp57 was detected at an apparent higher
molecular weight than ERp57 in platelets, due to the
presence of a linker attached to the protein that is non-
cleavable. Using an assay based on the continuous reduction
of the ﬂuorescent substrate DI-E-GSSG over time [21] we
observed that recombinant ERp57 (50 nM) has redox activity
(Fig. 1B) and that anti-ERp57 (37.5 lg mL)1) is able to
inhibit this activity by 45% (± 13.8%, Fig. 1B,C). The
potential cross reactivity of anti-ERp57 with other closely
related platelet thiol isomerase family members was ruled out
in the same way using recombinant PDI, ERp72 and ERp5
(Fig. 1D–F respectively). Data from these experiments and
also immunoblots of recombinant ERp57, ERp72, ERp5
and PDI proteins probed using anti-ERp57 (Fig. 1G) reveal
that anti-ERp57 does not bind to or inhibit the activity of
these enzymes.
ERp57 regulates platelet aggregation and granule secretion
Anti-ERp57 antibodies were used to investigate the importance
of ERp57 for human platelet responses. Platelets were stimu-
lated with the collagen-receptor (GPVI)-selective ligand CRP-
XL (1 lg mL)1) following incubation (5 min) with varying
concentrations of anti-ERp57 or pre-immune control IgG.
Prior to the addition of inhibitory anti-ERp57, platelets were
incubated with a saturating concentration of F(ab)¢ fragment
of mAb IV.3. to prevent IgG-mediated platelet activation
through FccRIIA [22]. Platelet aggregation in response to
CRP-XL was inhibited in a concentration dependant manner
following incubation with anti-ERp57 (Fig. 2A,B). At the
highest concentration of anti-ERp57 (37.5 lg mL)1), aggrega-
tion was almost abolished (91% inhibition ± 3.95%). No
inhibition of aggregation was observed following incubation of
platelets with pre-immune IgG. A control monoclonal anti-
ERp57 antibody was used to verify that the effects observed
using our afﬁnity puriﬁed polyclonal antibody were attribut-
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Fig. 1. The generation of anti-ERp57 activity blocking antibodieswhich selectively inhibit ERp57.Humanplatelets (4 · 106 cells) and recombinant protein
(0.75–0.016 lg) were separated by SDS-PAGE and immunoblotted to detect ERp57 (anti-ERp57, 1:1000 dilution in 2% (w/v) skimmedmilk powder/TBS-
T) and anti-sheep IgGHRP-conjugated antibody (1:4000 dilution in 2% (w/v) skimmed milk powder/TBS-T) then developed using by chemiluminescence
(A). The ability of anti-ERp57 (37.5 lg mL)1) to inhibit the activity of recombinant ERp57 (50 nM) was measured by ﬂuorescence substrate-based thiol
isomerase assay (B). Anti-ERp57 was incubated with enzyme for 5 min prior to addition to 500 lL DI-E-GSSG substrate in the presence of 5 lM DTT
(closed circles: enzyme alone, open squares: enzyme with anti-ERp57). Enzyme activity was calculated and % inhibition of ERp57 activity at 30 min
demonstrated in graph (C). Cross reactivity of anti-ERp57 with recombinant (D) PDI, (E) ERp72, (F) ERp5 (all 50 nM) was measured by thiol isomerase
assay and (G) immunoblotting (5 lg recombinant enzyme/lane). Immunoblots were stained with coomassie blue stain to reveal protein loading (H).
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able to enzyme function blocking activity. Human platelets
were stimulated with CRP-XL (1 lg mL)1) following incuba-
tion (5 min) with puriﬁed mouse IgG (Fig. S1A), monoclonal
anti-ERp57 (Fig. S1B, both 37.5 lg mL)1) or the pan thiol
isomerase inhibitor bacitracin (3 lg, Fig. S1C). No difference
in aggregation between the IgG and mAb treated platelets was
observed, while, the positive control bacitracin substantially
inhibited platelet aggregation as previously observed [6,28]
(Fig. S1D). Thiol isomerase assays using mAb anti-ERp57
(dashed line), mouse IgG (dotted/dashed line) and sheep IgG
(dotted line) showed no inhibition of the enzymic activity of
ERp57 (Fig. S1E), whereas as shown in Fig. 1B anti-ERp57
(solid line) inhibited ERp57 activity.
To examine whether the observed inhibition of aggregation
was due to early disruption of platelet signalling and prevention
of the positive feedback effects of granule contents, dense
granule secretion was measured. Consistent with the effects on
platelet aggregation, pre-incubation with anti-ERp57 inhibited
dense granule secretion, with 37.5 lg mL)1 anti-ERp57 almost
entirely preventing ATP secretion (97% inhibition ± 0.78%)
in response to 1 lg mL)1 CRP-XL (Fig. 2C,D).
Previous reports have demonstrated that thiol isomerase
inhibition diminishes alpha-granule secretion [2,28]. PF4
release was measured by ELISA to determine if ERp57 plays
a role in the regulation of alpha granule secretion. PF4 release
from activated platelets in the presence of anti-ERp57
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Fig. 2. ERp57 regulates human platelet aggregation and granule secretion. Washed human platelets or PRP (4 · 108 cells mL)1) were pre-incubated with
IV.3 F(ab)¢ fragment for 1 min and then either 37.5 lg mL)1 pre-immune IgG or anti-ERp57 (12.5–37.5 lg mL)1) for 5 min. For aggregometry, platelets
were stimulated with 1 lg mL)1 CRP-XL and traces recorded for 90 s (A); graph (B) shows % inhibition of aggregation normalised to pre-immune IgG-
treated samples. For dense granules, secretion in response to 1 lg mL)1 CRP-XL was recorded for 180 s (C) and % ATP secretion normalised to pre-
immune IgG-treated samples (D). Platelet factor 4 (PF4) secretion from alpha granules was measured by ELISA. Washed human platelets
(4 · 108 cells mL)1) were incubated with either pre-immune IgG (37.5 lg mL)1) or anti-ERp57 (37.5 lg mL)1) for 5 min prior to stimulation (1 lg mL)1
CRP-XL). (E) Absorbance values (PF4 levels) from cells stimulated in the presence of anti-ERp57 (open histogram) are presented alongside values
obtained for cells incubated with pre-immune IgG (ﬁlled histogram), n = 5, *P < 0.05. (F) cell surface P-selectin exposure following stimulation with
CRP-XL (1 lg mL)1) in the presence of either pre-immune IgG (37.5 lg mL)1, black graph) or anti-ERp57 (37.5 lg mL)1, white graph) wasmeasured by
ﬂow cytometry, n = 3.
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(37.5 lg mL)1) was found to be reduced modestly
(31% ± 19.7% reduction) when compared to the levels
observed for pre-immune IgG treated cells (37.5 lg mL)1,
Fig. 2E). The effect of ERp57 inhibition on P-selectin exposure
was determined by ﬂow cytometry, upon stimulation with 1 lg
mL)1 CRP-XL. Both pre-immune IgG- and anti-ERp57-
treated cells displayed a dramatic increase in cell-surface P-
selectin levels, with no mean difference (Fig. 2F).
Given the effects on aggregation and secretion we were
interested to determine if early signalling downstream of GPVI
was affected by ERp57 inhibition. Calcium ﬂux was measured
by ﬂuorimetric assay [24]. In the presence of pre-immune IgG
(37.5 lg mL)1) calcium ﬂux was rapid with a mean time to
peak ﬂuorescence of 36 s (± 3.16 s) whereas anti-ERp57
(37.5 lg mL)1) delayed the time to peak to 59 s (± 5.44 s,
Fig. 3A,B). Peak ﬂuorescence levels were also reduced by
53.7% in the presence of anti-ERp57, compared with pre-
immune IgG treated cells (data not shown). Previous reports
using anti-ERp5 inhibitory antibodies, showed that ERp5
inhibition did not impact on calcium mobilisation [2], whereas
ERp57 inhibition markedly decreases and delays cytosolic
calcium elevation possibly through inhibition of mobilisation
or inﬂux. These data together with the alpha granule data
suggest that within the thiol isomerase family, different family
members interact with distinct cell-surface proteins and/or
signalling pathways with potentially differing modes of action.
Fibrinogen binding is inhibited by ERp57
Since a-granule secretion and therefore ﬁbrinogen secretion is
less sensitive to the inhibition of ERp57, we investigated
whether the inhibition of aggregation was due to an impair-
ment of aIIbb3 activation. Indeed, inhibition of ERp5 or PDI
has been shown to exert an inhibitory effect on this receptor,
preventing activation and ﬁbrinogen ligation [2,5]. The levels of
ﬁbrinogen binding at the surface of human platelets was
assessed by ﬂow cytometry. ERp57 inhibition resulted in a
typical two-peaked proﬁle, representing two populations of
platelets – activated and non-activated (Fig. 4A). Compared
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*P < 0.05, **P < 0.01, ***P < 0.005.
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Fig. 4. ERp57 inhibition reduces platelet ﬁbrinogen binding. Fibrinogen
binding to integrin aIIbb3 in the presence of either pre-immune IgG
(37.5 lg mL)1, ﬁlled histogram) or anti-ERp57 (37.5 lg mL)1, open his-
togramwasmeasured by ﬂow cytometry. Human platelets were stimulated
with CRP-XL (1 lg mL)1) and ligated ﬁbrinogen detected using FITC-
labelled anti-ﬁbrinogen antibody (A). Fluorescence data for pre-immune
IgG and anti-ERp57 treated cells from 3 platelet donors (B), *P < 0.05.
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with the pre-immune IgG treated platelets, anti-ERp57 pre-
incubation was found to decrease CRP-XL stimulated binding
of ﬁbrinogen to platelets by 67% (± 6.0%, Fig. 4B).
ERp57 inhibition effects adhesion and integrin mediated
signalling
Previous reports have demonstrated that thiol isomerase
activity is important for integrin-mediated adhesion [2,5].
Adhesion to collagen and ﬁbrinogen coated surfaces was
measured by static adhesion assay as described previously [26].
Platelet adhesion following pre-incubation with anti-ERp57
(12.5, 25 or 37.5 lg mL)1) was inhibited in a concentration-
dependant manner on both matrices (Fig. 5A,B). At the
highest concentration examined (37.5 lg mL)1), anti-ERp57
inhibited adhesion onto collagen by 65% (± 26.5%) and onto
ﬁbrinogen by 83.7% (± 34%).
In addition to the effects on initial platelet signalling and
later events we observed that during the antibody generation
process, immunisation with recombinant ERp57 caused a
progressive defect in clot formation following blood sampling
from the sheep. To investigate whether this defect was due to an
effect on outside in signalling through integrin aIIbb3, clot
retraction assays were performed [29]. Figure 5C shows
representative clots which were retracted over a period of 2 h
in the presence of either pre-immune IgG or varying concen-
trations of anti-ERp57. Analysis of the weight of each clot
revealed that clots formed in the presence of pre-immune IgG
(37.5 lg mL)1) were fully retracted with a mean weight of
0.047 g (± 0.011 g) whereas the presence of anti-ERp57
caused inhibition of clot retraction with clots weights as
follows: 0.275 ± 0.027 g (37.5 lg mL)1), 0.084 ± 0.020 g
(25 lg mL)1) and 0.055 ± 0.0068 g (12.5 lg mL)1, anti-
ERp57, Fig. 5D). These data are consistent with the ability
of ERp57 to modulate both inside-out platelet integrin
signalling, and the outside-in integrin signalling that accompa-
nies platelet activation.
ERp57 effects thrombus formation
In order to assess the potential physiological signiﬁcance of
ERp57, an in vitro thrombus formationmodel was used.Whole
human blood labelled with DIOC6 was perfused through
collagen coated glass capillaries at an arterial shear rate of
1000 s)1 in the presence of either pre-immune IgG or anti-
ERp57 (both 37.5 lg mL)1). Adherent thrombus volume was
quantiﬁed by confocal microscopy. Capillaries from pre-
immune IgG treated blood showed widespread coverage with
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Fig. 5. ERp57 is involved in integrinmediated adhesion and clot retraction.Microtitre plates were coated with (A) collagen (20 lg mL)1) or (B) ﬁbrinogen
(1 mg mL)1). Platelets pre-treated with F(ab)¢ fragment of IV.3 antibody and then incubated with either pre-immune IgG (37.5 lg mL)1) or anti-ERp57
(12.5–37.5 lg mL)1) were allowed to adhere. Adherent cells were lysed with acidic lysis buﬀer and the assay developed using p-NPP substrate. Absorbance
data represent 4 separate experiments, **P < 0.01, ***P < 0.005. Clot retraction was measured using human PRP adjusted to 4 · 108 cells mL)1. Cells
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concentrations of anti-ERp57 after 2 h and (D) mean data for clot weight. n = 4, *P < 0.05, **P < 0.01.
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thrombi (Fig. 6A) whereas the capillaries from anti-ERp57
treated blood showed sparse thrombus coverage (Fig. 6B).
Analysis of the volume of thrombi in multiple capillaries
revealed that ERp57 inhibition resulted in a 78% decrease in
thrombus volume compared to pre-immune IgG-treated blood
(Fig. 6C). These data are consistent with the observed effects
on platelet aggregation and adhesion onto collagen suggesting
that ERp57 plays an important role in both initial adhesion
and the formation of stable aggregates under arterial ﬂow
conditions.
ERp57 is released at sites of vascular injury and regulates
arterial thrombus formation
Having established that ERp57 plays an important role in the
regulation of platelet aggregation and integrin mediated events,
we sought to determine if extracellular ERp57 plays a role in
the regulation of arterial thrombus formation in vivo. This was
examined using a laser-induced model of thrombosis in mice
and visualised by intravital microscopy. Following infusion of
Alexa-488 labelled anti-ERp57 antibodies, time dependant
localisation of ﬂuorescence within the platelet thrombus was
observed (Fig. 7B), consistent with the binding of ERp57 to the
surface of platelets [3].
The importance of ERp57 in arterial thrombus formation
was determined using inhibitory and unlabelled anti-ERp57
and platelets labelled with anti-GPIb Alexa-488 conjugate.
Following laser-induced injury, integrated ﬂuorescence of the
thrombi formed, and therefore platelet accumulation, was
measured. Compared to the control IgG treated mice, throm-
bus formation in the presence of anti-ERp57 was reduced
substantially (83% reduction in mean peak thrombus ﬂuores-
cence levels) (Fig. 7C). These data are consistent with our
hypothesis that ERp57 located on the platelet surface is
important for arterial thrombus formation.
Discussion
Platelets contain multiple thiol isomerases which are released
and bind the cell surface [1–3,28]. One of these enzymes,
ERp57, is known to play diverse roles in other cell types but
until recently little was known of its role in platelet function. In
this study we demonstrate an important role for ERp57 in
multiple components of platelet function and arterial thrombus
formation.
ERp57 is a component of protein folding complexes in the
ER, it is involved in fertilisation and forms complexes with gene
transcription factors, making its genetic ablation embryonically
lethal. Genetic knockdown approaches have been deployed to
study the role of ERp57 but developmental adaptive effects
have complicated assessment of its function [30]. Other
approaches to thiol isomerase inhibition include the use of
the non-speciﬁc inhibitor bacitracin, thiol blocking reagents or
enzyme function blocking antibodies which thus far have
proved the most successful and allow for the targeting of
individual enzymes. Indeed these reagents have been key to
developing an understanding of the roles of PDI and ERp5 in
platelet function. Despite the availability of an antibody that is
reported to block ERp57 activity on the surface of spermato-
zoa [19], experiments using this antibody, showed no effect on
either platelet function or thiol isomerase activity (Fig. S1), and
therefore prior to this study, no reagents which selectively block
ERp57 activity at the platelet surface were available. We have
developed a function blocking antibody that allows for the
acute and selective inhibition of ERp57 function and for the
ﬁrst time have demonstrated the signiﬁcance of cell surface
ERp57 in platelet function.
Incubation of anti-ERp57 with human platelets in vitro
resulted in inhibition of both platelet aggregation and dense
granule secretion following stimulation with the GPVI agonist
CRP-XL. Pre-immune IgG and monoclonal anti-ERp57 did
not inhibit ERp57 enzymic activity or platelet responses to
agonist. The levels of inhibition are greater than observed in
previous reports in which both PDI and ERp5 were inhibited
using function blocking antibodies to both enzymes but where
complete inhibition was not observed. It is therefore possible
that ERp57 plays an important role normal platelet function.
ERp57 inhibitionwas found to have a distinct effect on calcium
ﬂux, causing a decrease in the levels and rate of change of
cytosolic calcium, whereas the inhibition of another closely
related enzyme, ERp5, has little effect on calcium mobilisation
[2].
Furthermore, in contrast with previous reports that show
both ERp5 and PDI regulate a-granule secretion, in this report
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Fig. 6. ERp57 modulates in vitro thrombus formation. Human whole
blood labelled with DIOC6 was incubated with either (A) pre-immune
IgG, 37.5 lg mL)1 or (B) anti-ERp57, 37.5 lg mL)1 for 5 min and then
perfused over collagen coated capillaries at a shear rate of 1000 s)1 for
3 min. Randomly selected ﬁelds were visualised and quantiﬁed by confocal
microscopy (images A and B) and thrombus volume measurements ob-
tained (C), n = 3, **P < 0.01.
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we determined using two different assays that a granule
secretion is less sensitive to the effects of ERp57 inhibition,
whereas dense granule secretion is inhibited substantially. Since
a-granule and therefore ﬁbrinogen secretion were normal in the
presence of anti-ERp57, we investigated ﬁbrinogen binding and
outside-in signalling following ﬁbrinogen ligation and found
that these were both impaired by ERp57 inhibition. It is
therefore possible that ERp57 at the cell surface may be
involved in the regulation of the redox changes associated with
activation of integrin aIIbb3 [31] leading to an enhancement of
ﬁbrinogen ligation and associated outside-in signalling. Taken
together these data are indicative of some fundamental
differences in the roles played by the different cell-surface thiol
isomerases in the regulation of platelet activation. The mech-
anisms that underlie the ability of extracellular ERp57 to
modulate dense granule secretion to a greater extent than a-
granule secretion will be of particular interest for future
characterisation.
Platelet adhesion on to collagen and ﬁbrinogen coated
surfaces was found to be reduced through the inhibition of
ERp57 in the absence of an activatory stimulus. We believe
that cell-surface ERp57 may be in part responsible for the
modulation of tonic signalling levels and that perturbations of
this lead to the observed reduction in initial adhesion which is
also likely to account for the decreased formation of thrombi
formed under in vitro ﬂow conditions.
Using an in vivo approach we have determined that like
PDI [8], ERp57 is secreted at the site of vascular injury,
where it begins to accumulate within the platelet thrombus.
Inhibitory anti-ERp57 was found to decrease arterial throm-
bosis suggesting that extracellular ERp57 within a developing
platelet thrombus acts as a positive regulator of the thrombus
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Fig. 7. ERp57modulates arterial thrombus formation in vivo.The presence of ERp57 in thrombi and its role in arterial thrombus formation was examined
by intravital microscopy using a laser injury model. Alexa-488 labelled control-IgG (A) or anti-ERp57 (B) were infused into C57/BL6 mice, and following
laser injury images were captured over 2 min of thrombus formation (n = 3). (C) The eﬀect of anti-ERp57 on arterial thrombus formation was quantiﬁed
following laser injury in mice treated with Alexa-488 anti-GPIb-conjugated antibody. Arrows denote the site of the thrombus. Peak integrated thrombus
ﬂuorescence measurements for thrombi formed in the presence of anti-ERp57 (open histogram) treated mice were compared to those obtained for control
IgG (closed histogram). n = 24, ***P < 0.005.
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formation process. Furthermore, ERp57 release following
GPVI stimulation of human platelets, has been reported to
support the activation of tissue factor leading to increased
activation of coagulation [32]. The inhibition of ERp57 at
sites of arterial thrombosis may therefore also impact on the
regulation of coagulation along with other released thiol
isomerases. The ERp57 recruited to platelet thrombi may be
derived from platelets themselves, as we have shown in vitro
in isolated platelet preparations [3], but additional sources
such as laser-damaged/activated endothelium may also con-
tribute. Indeed human umbilical vein endothelial cells have
been shown to express both ERp57 [3] and PDI, and laser
injury has been shown to cause PDI release from endothelial
cells [8].
Based on the data presented in this report, we propose
that ERp57 plays an important role in both the regulation of
the initial events leading to platelet activation and the later
stages which support arterial thrombus formation. ERp57
shares some mechanistic overlap with the other platelet thiol
isomerases ERp5 and PDI, but emerging data indicate
distinctive substrate speciﬁcities, binding partners and mech-
anisms of action by different members of the platelet thiol
isomerase family at the platelet surface. While further
understanding of the speciﬁc substrates of the individual
thiol isomerases is required, our working hypothesis is that
ERp57 becomes enriched on the surface of activated platelets
and serves to enhance or stabilise the transition in integrin
afﬁnity from an inactive state to a ligand binding conformer
by catalysing the remodelling of disulphide bonds within the
receptor itself or other, as of yet unidentiﬁed substrates. This
results in enhanced platelet adhesion, aggregation, outside-in
signalling, and therefore activation and thrombus formation
levels. We recently reported the identiﬁcation of a further
four platelet-surface thiol isomerase enzymes, ERp72,
ERp44, ERp29 and TMX3 [3] which together with ERp57,
ERp5 and PDI may contribute to a paradigm for platelet
regulation that is of physiological importance for haemostasis
and thrombosis.
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